BioReliance, the biologics and early-development services business under Sigma-Aldrich Corporation’s (SIAL) Specialty Fine Chemicals (SAFC) segment, commissioned a new world-class Clearance Services ...

BioReliance, a Rockville, Md.-based provider of biologic safety and specialized toxicology testing services, may finally have settled down after bouncing among three owners since 2004. During C&EN’s ...

Life science and technology company, Sigma-Aldrich Corporation (NasdaqGS:SIAL - News) announced that it has agreed to buy BioReliance Holdings Inc., from private equity firm Avista Capital Partners ...

ROCKVILLE, Md., Sept. 12 BioReliance Corporation, aleading contract services organization for the biopharmaceutical andpharmaceutical industries, has contracted with Gentronix to offer ...

ST. LOUIS, Jan. 9, 2012 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ:SIAL), a leading Life Science and High Technology company, announced it has signed an agreement to acquire BioReliance ...

ROCKVILLE, Md.--(BUSINESS WIRE)--BioReliance Corporation announced today that David A. Dodd has been named President, Chief Executive Officer and Chairman of the Board of the Company, effective today.

BioReliance signed an agreement to acquire the colonies required for the Big Blue® transgenic rodent (mice) mutation (TRM) assay and to obtain a license to its associated trademark from Agilent ...

BioReliance has introduced select in vitro ADME (absorption, distribution, metabolism and excretion) and toxicology testing services its service offering. The company#&39;s range of predictive assays ...

--(BUSINESS WIRE)--BioReliance Corporation is a leading provider of cost-effective contract services, offering more than 1,000 tests or services related to biologics safety testing, specialized ...

Invitrogen's deal to sell its pharmaceutical services division, BioReliance, came at a hefty discount. Less than three years after paying $500 million for the unit, the company announced yesterday ...

CARLSBAD, Calif. -- Invitrogen Corp. announced plans to buy rival BioReliance Corp. for about $384 million. Invitrogen, after the maker of tools used in biotechnology research, said it will offer $48 ...

NEW YORK (CBS.MW) -- Biotechnology stocks fell Wednesday, with shares of BioReliance Corp. losing a third of their value after the company said first-quarter profit would be down from the previous ...